Reported results
- Total revenue was $0.7 million for the third quarter of 2026.
- Cost of revenue was $0.9 million for the third quarter of 2026.
- Research and development expense was $2.1 million for the third quarter of 2026.
- Selling, general and administrative expense was $5.2 million for the third quarter of 2026.
- Operating loss was $7.5 million for the third quarter of 2026.
- Net loss was $8.7 million, or $1.14 per share, for the third quarter of 2026.
Notes
During the quarter, Plus Therapeutics rebranded as Cerenome.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-13 (8-K, Item 2.02). Read the original filing on sec.gov.
